-+ 0.00%
-+ 0.00%
-+ 0.00%

AnGes starts rolling BLA submission to FDA for HGF gene therapy in PAD patients

PUBT·07/17/2026 00:01:56
Listen to the news
AnGes starts rolling BLA submission to FDA for HGF gene therapy in PAD patients
  • AnGes began submitting a US BLA for its HGF gene therapy beperminogene perplasmid to treat chronic limb-threatening ischemia.
  • The FDA addressed pre-BLA questions in writing, backed the planned rolling submission, making the July 16 pre-BLA meeting unnecessary.
  • AnGes said the meeting cancellation will not affect consolidated financial results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnGes Inc. published the original content used to generate this news brief on July 17, 2026, and is solely responsible for the information contained therein.